HLA-C and non-small cell lung carcinoma: Similarly, dendritic cell-derived EVs (Dex), loaded with MHC class I and II-restricted cancer antigens, have been reported to serve as effective maintenance therapy in non-small cell lung cancer (NSCLC) via boosting of natural killer (NK) cell arm of antitumor immunity [27].